EP PerMed Joint Transnational Call (JTC) 2026 “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (CARMEN2026)

EP PerMed Joint Transnational Call (JTC) 2026 “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (CARMEN2026) is sponsored by European Partnership for Personalised Medicine (EP PerMed) / European Union (Horizon Europe). This opportunity supports mission-aligned projects and measurable outcomes.

EP PerMed Joint Transnational Call (JTC) 2026 - European Partnership for Personalised Medicine - EP PerMed Direkt zur Hauptnavigation EP PerMed Joint Transnational Call (JTC) 2026 Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026) Announcement for the Joint Transnational Call (JTC) 2026 The European Partnership for Personalised Medicine, EP PerMed (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action “ The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023) ”, SRIA for PM (2023), through dedicated research, development and innovation funding.

The EP PerMed funding organisations listed below have agreed to launch the joint transnational call 2026 (JTC2026) “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (acro-nym: CARMEN2026), co-funded by the European Union, to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field.

The JTC2026 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the French National Research Agency, (ANR), FRANCE. The call will be implemented in two stages, i.e. a pre- and a full proposal phase. The available budget for this call is 38 Mio.

€ (approx.) .

Expected timeline of the call Date Event 25 November 2025 Publication of the call 16 December 2025 Information day (recording & slides available) 10 February 2026 (14:00, CET) Deadline for pre-proposal submission Expected around 05 May 2026 Communication of the results of the pre-proposal assessment and invitation to the full proposal stage 09 June 2026 (14:00, CEST) Deadline for full proposal submission Mid/end of August 2026 Rebuttal stage Expected for October 2026 Communication of the funding decisions to the applicants End of 2026, beginning of 2027 Expected project start (according to regional/national funding regulations) An information day introducing the JTC2026 to the research community will be organised on 16 December 2025, 10:00 AM CET.

Electronic submission website Contact persons for the Joint Call Secretariat (JCS) The EP PerMed JCS is hosted by the French National Research Agency (ANR), France: Phone: +33 01 73 54 83 32 Email: eppermed@agencerecherche. fr EP PerMed Partnering Tool The EP PerMed partnering platform is an online networking tool for finding cooperation partners in personalised medicine research.

It can be used to connect specifically in the context of the current CARMEN2026 call.

Guidelines for applicants (Annex I; ISCIII, page 96 – contact point) Guidelines for applicants (Section 3, page 6; CSCJA, pages 104-106) Guidelines for applicants (BMG, page 43) Guidelines for applicants (RCN, pages 71-72) Guidelines for applicants (CVTI SR, pages 88-90) Guidelines for applicants (NKFIH, page 49) Added Cooperation with Breakthrough T1D Call Text (Annex III, page 32) Guidelines for applicants (BMFTR, pages 41-42), Call Text and Guidelines for applicants (SMWK (Germany, Saxony) is not participating in the call as funder) Guidelines for applicants (BMFTR, pages 41-42) Change of a funders name: ISERD (Israel Innovation Authority) to IIA (National Technological Innovation Authority) Publication of the Pre-Announcement Guidelines for Applicants (PDF) Depending on the country of origin, additional documents may be required.

Please note: This list is not exhaustive. Please consult the “ Guidelines for Applicants ” and its Annex III as main reference document for applicants concerning individual funders regulations/requirements applicable in this call. National submission online at https://elane.

fwf. ac. at via the programme category “PIK – International Projects” (pre-proposal)” (deadline for submission is 11 February 2026 (14:00 CET)).

Applicants to F. R. S.

-FNRS funding must submit their pre-proposal an administrative application on e-space within 5 working days after the general deadline of the EP PerMed call to be eligible . Please select the “PINT-MULTI” funding instrument when creating the administrative application. Applicants for FWO funding must submit a mandatory administrative application through FWO’s e-portal .

The national submission deadline matches the joint transnational call’s pre-proposal stage. Czech Republic (MZCR/AZVCR) Additional national documents (to be submitted by the same deadline established in the joint transnational call: Conditions for Czech applicants (PDF) ). National additional document (to be sent to CSO-MOH before the JTC submission deadline, instructions (DOCX) ).

Pre-eligibility check form for IT-MoH proposals (PDF) (to be sent to IT-MoH at least 10 working days before the JTC submission deadline). Pre-eligibility check form for FRRB proposals (DOCX) (to be sent to FRRB at least 10 working days before the JTC submission deadline) and budget tool (XLSX) as support for FRRB applicants.

Pre-eligibility check form (DOCX) for Tuscany Region proposals and budget compilation (XLSX) form for Tuscany Region proposals (pre-eligibility form to be sent to RT at least 10 days before the JTC submission deadline). Statement of Commitment for FCT proposals (to be sent up to 10 working days after the deadline for submission of pre-proposals to the National Contact Points, EPPerMed@fct. pt ).

SAMRC Pre-eligibility Check form (to be sent by 26 January 2026, 23:00, CET). Additional document for CFN proposals (DOC) (to be sent to CFN in parallel to the pre-proposal submission).

Cooperation with Breakthrough T1D – CARMEN2026 In the framework of the Joint Transnational Call (JTC) 2026 “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (CARMEN2026), Breakthrough T1D offers the opportunity for researchers based anywhere in the world to participate as self-funded partners in successfully selected proposals with a clear focus on Type 1 Diabetes (T1D).

Researchers interested in linking their participation to Breakthrough T1D are required to contact Breakthrough T1D at least 15 working days before the JTC pre-proposal deadline (email to churtadodelpozo@breakthrought1d. org ) to discuss scientific alignment and procedural requirements.

Any potential involvement or support from Breakthrough T1D is subject to a separate internal review and approval process and is not automatically guaranteed through participation in the JTC. Cooperation with Xjenza Malta For the JTC2026, EP PerMed is cooperating with the Maltese funding agency Xjenza Malta .

Through the Access2Partnerships (A2P) Scheme , Malta-based researchers can participate in the EP PerMed Call as partners on own funds and may be eligible for up to €300,000 per project to support their involvement in a successfully selected proposal, subject to a successful national application to Xjenza Malta.

Applicants need to submit a short administrative form to Xjenza Malta at least 15 working days before the pre-proposal submission deadline . More information can be found here . The overall objectives of the JTC2026 will be to Fund research projects in human health on innovative PM strategies for patients with cardiovascular, metabolic or kidney diseases.

Research projects may focus on a single disease or explore these conditions in combination. Proposals should address one or more of the following aspects: Development and validation of innovative personalised therapeutic approaches for cardiovascular, metabolic or kidney diseases through testing in relevant pre-clinical models (e.g., human cell cultures, organoids, organs-on-chips, disease-specific animal models, or in silico models).

Identification and validation of molecular markers/signatures or cutting-edge technologies (see also point 2 below) to monitor treatment response in patients with cardiovascular, metabolic or kidney diseases in order to tailor treatment pathways . This may include the analysis of the treatment effectiveness or treatment-related (including multi-medication) adverse effects as well as dose optimisation.

Identification and validation of stratifying molecular markers/signatures or stratifying diagnostic technologies for early disease risk prediction and prevention of disease worsening or comorbidities in patients with cardiovascular, metabolic or kidney diseases, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.

Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.

Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations. Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Research projects that combine a personalised medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular, metabolic and kidney diseases are welcome. Projects are encouraged to combine the following aspects in their research: Multi-omics data such as genomics, epigenomics, metagenomics, transcriptomics, proteomics and metabolomics data in relation to treatment outcomes.

These data may be obtained from health data platforms or infrastructures, including population-level health databases. Cutting-edge technologies such as AI/ML algorithms, next-generation imaging technologies, digital health tools, etc. to enhance early diagnosis, monitor treatment response, optimise therapy effectiveness or dosage, and detect or prevent comorbidities and treatment-related side effects in patients.

Information regarding patient medication, dose or compliance, medication efficacy, adverse effects, patient reported outcomes (PRO) or patient preferences. Additional factors such as sex/gender dimension, age, environmental and social background, lifestyle, or nutritional status. Participatory research should be established in that active representation of patients or citizens is part of research projects.

EP PerMed is supporting this approach by providing dedicated funding to organisations representing patients or citizens to participate as partners in proposals submitted to this call. Those organisations could support in designing the research, ensuring that research questions are relevant from the patients’ and citizens’ point of view. They might also support in collecting data for PROs and adverse effects.

Projects funded under this call are furthermore required to include a dedicated work package focussing on the question of the translation or implementation of the research outcomes into clinical practice with a focus on e.g. patient outcome, patient preferences, costs, reimbursement, education (to healthcare providers, patients and citizens), ELSA (ethical, legal and societal aspect) or accessibility at the point of care.

Please refer to the Call Text of the JTC2026 for further information and definitions.

General (Eligibility) Conditions for Application Joint research proposals may be submitted by applicants belonging to an entity according to the following categories (subject to regional/national funding regulations; see “Guidelines for Applicants”): Academia (research teams working in universities, other higher education institutions) or research institutes; Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations).

Participation of clinicians (e.g. medical doctors, nurses), pharmacists and general practitioners in the research teams is encouraged; Private for-profit (industry) partners, e.g. SME (small and medium-sized enterprises) and private non-profit partners , e.g. foundations, associations or non-governmental organisations.

Consortia submitting applications to this call are strongly encouraged to include partners from different categories (A, B and C) in line with the crosscutting/multidisciplinary nature of the call, where the aim is to include partners at different levels in the value chain.

It is also strongly recommended to integrate at least one early-career researcher (ECR) as principal investigator in a consortium (for the EP PerMed definition of ECR, please consult the Annex III of the “Call Text”). Only transnational projects will be funded. Each consortium must involve at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call.

Each of these partners must be eligible and request funding from the respective funding organisation. All three legal entities must be independent of each other . The project coordinator must be eligible to be funded by their regional/national participating funding organisation.

The project coordinator (i.e. principal investigator and organisation) cannot be changed between the first and second stage. Max. 2 project partners per consortium can request funding from the same funding organisation.

For some funding organisations, the maximum number of eligible partners who can be funded in one project is limited to one (see also “Guidelines for Applicants” for individual funding rules). No more than one partner on own funds is allowed in the consortia with at least three partners eligible for funding (more indications in the Call Text: “B. Funding recipients”, section 7).

Maximum number of partners is 6 (no more than 2 partners from the same country including partners on own funds); Maximum number of partners can be 7 if the consortium includes a 3 rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium; including partners on own funds).

Consortia are allowed to include in the full proposal phase an additional project partner that is eligible to receive funding from a funding organisation that is underrepresented in the second stage of the call and that agrees to participate in the widening option(a list of underrepresented regions/countries will be provided to coordinators invited to submit full proposals).

The rules for the consortium composition need to be respected, i.e. the final number of partners can only sum up to 7 or 8 if there are 3 partners of the same country in a consortium ( condition : funding requested from at least 2 different funders of the respective country; applies to only one country per consortium, including partners on own funds).

To facilitate the integration of organisations representing patients or citizens in consortia, they can be added as additional partners at the pre-proposal stage or full proposal stage. Organisations representing patients or citizens can be added as additional partner(s) either on own funds or by applying for funding, if eligible, from EP PerMed (see page 10 of the call text) or the respective funding organisations.

The consortia must follow all of the above-mentioned rules regarding the consortia composition without counting the patient/citizen representing organisations, except for the following rule: within one consortium, no more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations.

For some funding organisations, the maximum number of eligible partners who can be funded in one project is one. Each project partner has to be represented by one principal investigator . Within a joint proposal, each project partner’s principal investigator will be the contact person for the JCS and the relevant regional/national funding organisation.

Each consortium must nominate one project coordinator among the project’s principal investigators. The nomination of a project co-coordinator is not allowed. If a partner is found to be ineligible by one of the funding organisations after the formal check, the entire proposal may be rejected without further review.

For a definition of eligible partners, see “Guidelines for Applicants”, the regional/national regulations, and contact the concerned regional/national funding organisation. A maximum project duration of 3 years may be applied for.

Number of partners in the proposal* Pre-proposal Full-proposal (only by inclusion of one underrepresented region/country) 3 4 5 6 7 +1 Maximum number of partners with own funding** 0 1 1 1 1 1 Maximum number of partners per country*** 1 2 2 2 3 3 (if the number of partners in the full proposal stage sums up to 7 or 8) * minimum of three partners eligible for funding from three different EU Member States countries, or two EU Member States and at least one Associated Country whose funders participate.

Patient/citizen representing organisations are not included in this calculation. ** patient/citizen representing organisations are not included in this calculation and can be added as partners participating with own funding at the pre- and full proposal stage.

*** maximum number of partners in the pre-proposal phase can be 7 if the consortium includes a 3 rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium, including partners on own funds).

Patient/citizen representing organisations are not included in this calculation and can be added as additional partners in the pre-proposal or full proposal stage. They can participate either on own funds or apply for funding, if eligible, from the regional/national funding organisation or EP PerMed.

Please note: within one consortium, not more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations. For some funding agencies, the maximum number of eligible partners who can be funded in one project is one. All eligibility criteria and submission requirements are detailed in the following two call documents: “Call text” and the “Guidelines for Applicants”.

The following countries (27) are participating in the preparation of the call: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Romania, Slovak Republic, South Africa, Spain, Sweden, The Netherlands and Turkiye (contact list is provided below).

Five of the participating countries are represented by their specific regions (9): Flanders (Belgium), Wallonia-Brussels Federation (Belgium), Lombardy (Italy), Tuscany (Italy), Azores (Portugal), Centro Region (Portugal), Andalusia (Spain), Catalonia (Spain) and Navarre (Spain).

Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EP PerMed funding organisation respective of the region/country from which applicants applies. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations.

Applicants are strongly advised to contact their regional/ national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below “ Contact list ”). List of Regional/National Contacts Name of participating organisation Country/Region Regional/National contact Austrian Science Fund, (FWF) Austria Hannes Zwickl Tel.

: +43 676 83487 8220 The Research Foundation – Flanders, (FWO) Belgium (Flanders) Kristien Peeters (SBO) europe@fwo. be Fund for Scientific Research – FNRS, (F. R.

S. -FNRS) Belgium (Wallonia-Brussels Federation) Maxime Bonsir maxime. bonsir@frs-fnrs.

be international@frs-fnrs. be The Ministry of Health of the Czech Republic / Czech Health Research Council, (MZCR/AZVCR) Czech Republic Monika Kocmanova Monika. kocmanova@azvcr.

cz Olga. laaksonen@mzd. gov.cz Tel.

: +420 604 786 141 Innovation Fund Denmark, (IFD) Denmark Rebecca Stiig Vibæk rebecca. stiig. vibaek@innofond.

dk internationale@innofond. dk Tel. : +45 6190 5076 Estonian Research Council, (ETAG) Estonia Margit Suuroja Tel.

: +372 515 3424 Research Council of Finland (AKA) Finland Rita Rinnankoski-Tuikka rita. rinnankoski-tuikka@aka. fi Business Finland, (BFRK) Finland Norma Saha norma.

saha@businessfinland. fi Tel. : +358 50 5577 012 Agence Nationale de la Recherche, (ANR) France Mylène Vaillancourt Tel.

: (+33) (0) 1 78 09 80 36 Tel. : (+33) (0) 1 72 73 06 72 EPPerMed@agencerecherche. fr Federal Ministry of Research, Technology and Space (BMFTR) German Aerospace Center e.

V. – Project Management Agency, (DLR) Germany Katja Kuhlmann Tel. : +49 228 3821-2211 Federal Ministry of Health, (BMG) German Aerospace Center e.

V. – Project Management Agency, (DLR) Germany Fabian Gondorf Tel. : +49 228 3821-2211 General Secretariat for Research & Innovation, (GRSI) Greece Foteini Karagkouni Tel.

: +30 213 1300132 National Research, Development and Innovation Office, (NKFIH) Hungary Zsuzsanna Kürti ncp@nkfih. gov.hu The Icelandic Centre for Research, (RANNIS) Iceland Helga Snævarr Kristjánsdóttir Helga. s.

kristjansdottir@rannis. is Taighde Éireann-Research Ireland, (TE-RI) Ireland Emma McGrath Emma. mcgrath@researchireland.

ie Chief Scientist Office, Ministry of Health, (CSO-MOH) Israel Liron Even-Faitelson Tel. : +972-2-5082168 National Technological Innovation Authority, (IIA) Israel Sarah Chiche sarah. c@innovationisrael.

org. il Tel. : +972 3 5118122 Italian Ministry of Health, (IT-MoH) Italy Maria Josefina Ruiz Alvarez mj.

ruizalvarez-esterno@sanita. it sc. ursu@sanita.

it Fondazione Regionale per la Ricerca Biomedica, (FRRB) Italy (Lombardy) Giulia Maria Rossignolo Tel. : +39 0267650159 Tuscany Region, (RT) Italy (Tuscany) Donatella Tanini eppermed@regione. toscana.

it Latvian Council of Science, (LZP) Latvia Maija Bundule Tel. : +371-29472349 Research Council of Lithuania, (LMT) Lithuania Živilė Ruželė Tel. : (+370) 676 14383 National Research Fund, (FNR) Luxembourg Gideon Gießelmann gideon.

giesselmann@fnr. lu Tel. : +352 691 362 805 The Research Council of Norway, (RCN) Norway Karianne Solaas Tel.

: +47 945 35 380 National Centre for Research and Development, (NCBR) Poland Anna Stępień Tel. : +48 22 39 07 210 Fundação para a Ciência e a Tecnologia, (FCT) Portugal Rita Cavaleiro EPPerMed@fct. pt Vice-Presidency of Azores Regional Government, (VP-GRA) Portugal (Azores) Maria Luís Adrião do Vale Maria.

LA. Vale@azores. gov.pt Tel.

: +351 296 308 922 Comissão de Coordenação e Desenvolvimento Regional do Centro, (CCDRC) Portugal (Centro Region) Sophie Patrício Tel. : +351 239 400 100 Executive Agency for Higher Education, Research, Development and Innovation Funding, (UEFISCDI) Romania Nicoleta Dumitrache nicoleta. dumitrache@uefiscdi.

ro mihaela. manole@uefiscdi. ro Centrum vedecko-technických informácií Slovenskej republiky, (CVTI SR) Slovak Republic Magdaléna Švorcová magdalena.

svorcova@cvtisr. sk erika. jankajova@cvtisr.

sk Tel. : +421 904 859 228 The South African Medical Research Council, (SAMRC) South Africa Rizwana Mia Tel: +27 21 938 0984 National Institute of Health Carlos III, (ISCIII) Spain Cándida Sánchez Barco eppermed@isciii. es Consejería de Salud y Consumo de la Junta de Andalucía, (CSCJA) Spain (Andalusia) Alicia Milano Curto ep.

fps@juntadeandalucia. es Health Department – Generalitat de Catalunya, (DS-CAT) Spain (Catalonia) Montserrat Llavayol Te. l: (+34) 935566103 Government of Navarre, (CFN) Spain (Navarre) Javier Larrea Tel.

: +34 848 42 76 47 Swedish Research Council, (SRC) Sweden Abraham Mellkvist-Roos Abraham. mellkvist-roos@vr. se Tel.

: +46 76 525 7613 The Netherlands Organisation for Health Research and Development, (ZonMw) The Netherlands Rob Diemel Tel. : +31 70 349 5252 The Scientific and Technological Research Council of Turkiye, (TUBITAK) Turkiye N. Selcan TÜRKER selcan.

turker@tubitak. gov.tr